Corcept Therapeutics (NASDAQ:CORT) stock plunged 5.03% in the intraday session on Tuesday, following the company's disappointing financial results for the full year 2024 and the fourth quarter.
For the full year 2024, Corcept reported revenue of $675.0 million, missing analyst estimates by 2.6%. Moreover, the company's earnings per share (EPS) of $1.35 fell short of analyst expectations by 13%, further exacerbating investor concerns.
The company's fourth-quarter performance was also lackluster, with revenue and EPS missing analyst estimates. Corcept's revenue of $181.9 million for the quarter was 8.5% below analysts' expectations, while its EPS figures were significantly below consensus estimates.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.